{
  "id": "5cd96f33a49efeb44c000004",
  "type": "factoid",
  "question": "What is the mode of action of filgotinib?",
  "ideal_answer": "Filgotinib is an oral selective Janus kinase 1 (JAK1) inhibitor. It has been tested in patients with rheumatoid arthritis and Chroni's disease, and has been shown to be effective.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30088677",
    "http://www.ncbi.nlm.nih.gov/pubmed/30360969",
    "http://www.ncbi.nlm.nih.gov/pubmed/27993829",
    "http://www.ncbi.nlm.nih.gov/pubmed/27993828",
    "http://www.ncbi.nlm.nih.gov/pubmed/27988142",
    "http://www.ncbi.nlm.nih.gov/pubmed/30360970",
    "http://www.ncbi.nlm.nih.gov/pubmed/28622463",
    "http://www.ncbi.nlm.nih.gov/pubmed/25681059",
    "http://www.ncbi.nlm.nih.gov/pubmed/28838249",
    "http://www.ncbi.nlm.nih.gov/pubmed/29566740",
    "http://www.ncbi.nlm.nih.gov/pubmed/26693854"
  ],
  "snippets": [
    {
      "text": "Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25681059",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26693854",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The selective Janus kinase 1 inhibitor filgotinib (GLPG0634), which is currently in clinical development for the treatment of rheumatoid arthritis (RA) and Crohn's disease, demonstrated encouraging safety and efficacy profiles in RA patients after 4 weeks of daily dosing. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26693854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In vitro, filgotinib and its active metabolite at clinically relevant concentrations did not interact with cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases, and did not inhibit key drug transporters. In the clinic, a lack of relevant pharmacokinetic drug interactions by filgotinib and its active metabolite with substrates of CYP3A4, as well as with organic anion transporters involved in methotrexate elimination were found.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26693854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622463",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we review the pharmacology and clinical trial data for efficacy and safety of filgotinib, an investigational selective JAK1 inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28838249",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The selectivity of filgotinib for JAK1 may have theoretical advantages in terms of limiting toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28838249",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993829",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993829",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993828",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993828",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The TORTUGA trial investigated the efficacy and safety of filgotinib, an oral selective Janus kinase 1 (JAK1) inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360970",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We aimed to investigate the efficacy and safety of filgotinib, a selective JAK1 inhibitor, for the treatment of psoriatic arthritis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360969",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30088677",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Filgotinib (GS-6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn's disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30088677",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29566740",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "JAK1 inhibitor"
}